{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000640","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2023-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.900257+00:00","generated_at":"2026-06-20T16:39:49.652409+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ginkgo expects to meet 2022 total revenue guidance of $460-480M; cash ~$1.3B","bullets":["Expects 55-60 new Cell Programs added in 2022, nearly doubling 2021 additions.","Foundry revenue expected below $150-170M guidance; Biosecurity revenue exceeds $310M.","Ended 2022 with approx. $1.3B cash; strong liquidity despite challenging macro.","Opened Bioworks7 (6,600 sq ft BSL-2 lab) for mammalian cell engineering; launched Ginkgo Enzyme Services.","Full audited Q4 and FY 2022 results due March 2023; 2023 outlook to be provided then."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000640","json":"https://secwatch.observer/filing/0000950170-23-000640.json","markdown":"https://secwatch.observer/filing/0000950170-23-000640.md","text":"https://secwatch.observer/filing/0000950170-23-000640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023000640/0000950170-23-000640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023000640/dna-20230111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:39:49.652409+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5eed84c9a03fd5f6da1bfb9375a1f76d36e0cbdb","claim":"Ginkgo Bioworks Holdings, Inc. reported the year ended December 31, 2022 results: revenue $460 – 480 million. Guidance reaffirmed.","evidence_excerpt":"Key Performance Highlights • Ginkgo reiterated its expectations of 55-60 new Cell Programs added to the Foundry platform in 2022 • Ginkgo continues to expect Total revenue of $460 – 480 million in 2022 o Preliminary unaudited Foundry revenue is expected to be below the previously disclosed guidance of $150 – $170 million in 2022 due to a subset of targeted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023000640/0000950170-23-000640-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$460 – 480 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}